POSSIBILITIES OF POSITRON-EMISSION TOMOGRAPHY IN DIAGNOSIS OF MALIGNANT BRAIN TUMORS (Literature Review)

Abstract

In the diagnosis of neoplasms at the preoperative and postoperative stages, positron emission tomography (PET) is the most informative method of radiation diagnosis, the main advantage of which is the determination of not only the structure and localization of tumors (as in the case of MRI and MSCT), but also the metabolic processes in them, which makes it possible to diagnose the tumor process at the earliest possible time, and also to delimit the continued growth of the tumor from pseudo-progression against the background of post-radiation necrosis. Nowadays, there is a fairly wide range of radiopharmaceuticals used for PET, with 18F-FDG and 11C-MET (18F-fluorodeoxyglucose and 11C-methionine) being the most clinically important. This review describes the location of positron emission tomography in the diagnosis of malignant brain tumors, and also points out the sensitivity of various radiopharmaceuticals with different brain pathologies, which is important with the ever wider introduction of this diagnostic method into clinical practice.

Keywords

• ПЭТ
• глиальные опухоли
• радиофармпрепарат